Raymond James Financial Services Advisors, Inc. Macrogenics Inc Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

1 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 Apr 14, 2023	BUY	$4.82 - $7.24 $88,606 - $133,092	18,383 New	18,383 $131,000

Others Institutions Holding MGNX

# of Institutions

132

Shares Held

55.4M

Call Options Held

215K

Put Options Held

238K

Bellevue Group Ag Kuesnacht, V8

9.93M
Shares

$32.4 Million
0.55% of portfolio
Armistice Capital, LLC New York, NY

6.26M
Shares

$20.4 Million
0.34% of portfolio
Black Rock Inc. New York, NY

5.4M
Shares

$17.6 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

4.36M
Shares

$14.2 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

3.54M
Shares

$11.5 Million
0.01% of portfolio

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account